NASP takes aim at DIR fees.
Class action lawsuits claim that chains colluded with PBMs to overbill customers.
Big changes for EpiPen and more in Express Scripts’ formulary.
A new study shows how the Medicare donut hole could be costing patients.
In a letter to the CMS, DIR fees take precedence
The PBM giant claims it is owed $14.5 million in fees.
Are PBMs responsible for higher drug prices or is something else to blame?
Amazon has massive resources, but it may struggle to enter the PBM marketplace.
Drug makers are starting plans to help patients pay for diabetes drugs.
How Inside Rx could save patients money.